Security Investigation
GSK plc (NYSE: GSK)
8 Days left to seek lead plaintiff status.
Contact a Lawyer Now
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 7, 2025 to file lead plaintiff applications in a securities class action lawsuit against GSK plc (NYSE: GSK).
GSK and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 10, 2022, a Deutsche Bank report highlighted that it was “very possible” that the Company and other Zantac distributors “will incur the risk of some degree of shared liability, with the only real questions being what the magnitude of liability may be.” Despite the Company’s statements to investors that scientific research did not support a correlation between Zantac and cancer, the Deutsche Bank report forecasted that total liability could be between $5 billion and $10 billion. On this news, the price of GSK’s ADRs fell $4.30 per ADR, or more than 10%. Then, on August 15, 2022, the Company disclosed that its liability exposure was between $1 billion and $10 billion. As a result of these disclosures, the price of GSK ADRs declined precipitously. On this news, the price of GSK’s ADRs fell an additional $1.08 per ADR, or 3%.
If you purchased ADRs of GSK and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or fill out the form on this page.
The case is Roofers Local No. 149 Pension Fund v. GSK plc, No. 25-cv-618.